Delayed Antibody and T-Cell Response to BNT162b2 Vaccination in the Elderly, Germany
Tatjana Schwarz
1, Pinkus Tober-Lau
1, David Hillus, Elisa T. Helbig, Lena J. Lippert, Charlotte Thibeault, Willi Koch, Irmgard Landgraf, Janine Michel, Leon Bergfeld, Daniela Niemeyer, Barbara Mühlemann, Claudia Conrad, Chantip Dang-Heine, Stefanie Kasper, Friederike Münn, Kai Kappert, Andreas Nitsche, Rudolf Tauber, Sein Schmidt, Piotr Kopankiewicz, Harald Bias, Joachim Seybold, Christof von Kalle, Terry C. Jones, Norbert Suttorp, Christian Drosten, Leif Erik Sander
2
, Victor M. Corman
2
, and Florian Kurth
2
Author affiliations: Charité–Universitätsmedizin Berlin, Berlin, Germany (T. Schwarz, P. Tober-Lau, D. Hillus, E.T. Helbig, L.J. Lippert, C. Thibeault, W. Koch, L. Bergfeld, D. Niemeyer, B. Mühlemann, C. Conrad, C. Dang-Heine, S. Kasper, F. Münn, K. Kappert, R. Tauber, S. Schmidt, P. Kopankiewicz, H. Bias, J. Seybold, C. von Kalle, T.C. Jones, N. Suttorp, C. Drosten, L.E. Sander, V.M. Corman, F. Kurth); Hausarztpraxis am Agaplesion Bethanien Sophienhaus, Berlin (I. Landgraf); Robert Koch Institute, Berlin (J. Michel, A. Nitsche); German Centre for Infection Research, Berlin (D. Niemeyer, B. Mühlemann, T.C. Jones, C. Drosten, V.M. Corman); Berlin Institute of Health, Berlin (C. Dang-Heine, K. Kappert, R. Tauber, S. Schmidt, J. Seybold, C. von Kalle); Labor Berlin–Charité Vivantes GmbH, Berlin (K. Kappert, R. Tauber); University of Cambridge, Cambridge, UK (T.C. Jones); G; erman Center for Lung Research, Gießen, Germany (N. Suttorp, L.E. Sander, F. Kurth); Bernhard Nocht Institute for Tropical Medicine, Hamburg, Germany (F. Kurth); University Medical Centre Hamburg-Eppendorf, Hamburg (F. Kurth)
Main Article
Table
Cohort characteristics in study of delayed antibody and T-cell response to BNT162b2 vaccination in the elderly, Germany*
Characteristic |
Healthcare workers
|
Elderly
|
No. patients
|
123
|
71
|
Sex |
|
|
|
|
F |
65 (52.9) |
54 (76.1) |
M
|
58 (47.2)
|
17 (23.9)
|
Median age, y (IQR)
|
34 (20–64)
|
81 (70–96)
|
Underlying conditions |
|
|
|
|
Cardiovascular disease |
15 (12.2) |
56 (78.9) |
Type 2 diabetes |
1 (0.8) |
13 (18.3) |
Respiratory disease |
16 (13.0) |
11 (15.5) |
Dyslipidemia |
5 (4.1) |
21 (29.6) |
Thyroid dysfunction |
0 |
16 (22.5) |
Chronic kidney disease |
0 |
12 (16.9) |
Chronic liver or GI disease |
2 (1.6) |
18 (25.4) |
Rheumatic disease |
6 (4.9) |
7 (9.9) |
Active solid malignancy |
2 (1.6) |
4 (5.6) |
Active hematological malignancy |
0 |
4 (5.6) |
Neurologic disease |
1 (0.8) |
18 (25.4) |
Immunodeficiency |
1 (0.8) |
0 |
Others
|
9 (7.3)
|
29 (40.9)
|
Outpatient medication |
|
|
|
|
No |
79 (64.2) |
5 (7.0) |
Yes |
39 (31.7) |
64 (90.1) |
Unknown |
5 (4.1)
|
2 (2.8)
|
Main Article
Page created: June 02, 2021
Page updated: July 18, 2021
Page reviewed: July 18, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.